DoSES

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

6 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This research is studying a vaccine against Mpox (formerly known as monkeypox) that is FDA approved for adults but not yet approved for children. The goal of the study is to determine if the vaccine protects children just as well as it protects adults. The study is also looking at the safety of the vaccine. This study is open to healthy adolescents, ages 12-17. In addition, adolescents with certain immunodeficiency diseases or other conditions, that are well controlled, are eligible to participate. 

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at DoSES [at] chop.edu or 267-293-9796.

Eligibility & Criteria

IRB #:
23-020826
Official Title:
A Phase 2 Randomized, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
Study Phase:
Phase II
Eligible Age Range:
12 - 17 Years
Gender:
All
Study Categories:
Downloadable Resources:

RECRUITMENT FLIER

Visit Criteria

Your participation would consist of your child completing the following:

  • Attend 9 study visits over a 13-month period. 8 study visits will be held in person at the CHOP Main Campus, and 1 study visit will be done over the phone.
  • Receive 2 doses of the Jynneos Mpox vaccine, 29 days apart
  • Have blood drawn at 5 of the 9 study visits

Participation is voluntary. There would be no cost to you, and you would be compensated for your time and effort.